PPM1K and cardiovascular disorder: Because of the similar metabolic characteristics of BCAA in various cardiovascular diseases, whether empagliflozin and other SGLT2 inhibitors could promote BCAA degradation in other cardiovascular diseases through similar mechanisms and how empagliflozin up-regulates PP2Cm remains to be revealed in further studies.